Vestcor Inc Makes New Investment in BioNTech SE (NASDAQ:BNTX)

Vestcor Inc bought a new position in BioNTech SE (NASDAQ:BNTX - Free Report) during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 6,600 shares of the company's stock, valued at approximately $784,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Planning Capital Management Corp grew its position in shares of BioNTech by 45,000.0% in the 3rd quarter. Planning Capital Management Corp now owns 451 shares of the company's stock valued at $54,000 after purchasing an additional 450 shares during the period. Blue Trust Inc. boosted its holdings in shares of BioNTech by 491.1% in the third quarter. Blue Trust Inc. now owns 467 shares of the company's stock valued at $55,000 after buying an additional 388 shares during the period. GAMMA Investing LLC increased its position in shares of BioNTech by 21.7% during the third quarter. GAMMA Investing LLC now owns 623 shares of the company's stock worth $74,000 after acquiring an additional 111 shares in the last quarter. Daiwa Securities Group Inc. increased its position in shares of BioNTech by 430.3% during the second quarter. Daiwa Securities Group Inc. now owns 1,925 shares of the company's stock worth $155,000 after acquiring an additional 1,562 shares in the last quarter. Finally, Caprock Group LLC acquired a new stake in shares of BioNTech during the second quarter worth $206,000. 15.52% of the stock is owned by institutional investors.

BioNTech Stock Performance

NASDAQ:BNTX traded down $0.31 during mid-day trading on Friday, hitting $120.38. The stock had a trading volume of 586,062 shares, compared to its average volume of 808,448. BioNTech SE has a twelve month low of $76.53 and a twelve month high of $131.49. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. The stock has a market cap of $28.62 billion, a price-to-earnings ratio of -57.32 and a beta of 0.22. The company's 50 day simple moving average is $113.86 and its 200 day simple moving average is $100.34.

BioNTech (NASDAQ:BNTX - Get Free Report) last released its quarterly earnings data on Monday, November 4th. The company reported $0.81 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.26) by $2.07. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The company had revenue of $1.24 billion during the quarter, compared to analysts' expectations of $514.08 million. During the same period last year, the firm posted $0.73 earnings per share. The business's revenue was up 38.9% on a year-over-year basis. On average, equities research analysts forecast that BioNTech SE will post -3.72 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on BNTX shares. Deutsche Bank Aktiengesellschaft upped their target price on shares of BioNTech from $95.00 to $150.00 and gave the stock a "buy" rating in a research note on Thursday, September 19th. Canaccord Genuity Group increased their price objective on BioNTech from $171.00 to $171.44 and gave the stock a "buy" rating in a report on Wednesday, November 27th. Morgan Stanley raised BioNTech from an "equal weight" rating to an "overweight" rating and lifted their target price for the company from $93.00 to $145.00 in a research report on Tuesday, September 24th. Jefferies Financial Group raised BioNTech from a "hold" rating to a "buy" rating and upped their price target for the stock from $96.00 to $150.00 in a research report on Tuesday, September 17th. Finally, UBS Group raised their price target on shares of BioNTech from $97.00 to $131.00 and gave the stock a "neutral" rating in a research note on Wednesday, September 18th. Four equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $140.76.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.